Physiological Finding in Management of COVID 19 Patients (COVID-19)

March 25, 2026 updated by: Chia-hsi Chen, St. Martin De Porress Hospital

The Combined Usage of Clinical Physiological Finding in Management of COVID 19 Patients

This study utilizes physiological indicators of COVID-19 patients as tools for assessing, tracking, worsening, and improving the clinical symptoms of COVID-19 patients. This study employs simple and easy-to-use assessment methods, which can be further aided by artificial intelligence technology to facilitate early response and medication.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

This study utilizes physiological indicators of COVID-19 patients, such as blood pressure, heart rate, respiratory rate, and level of consciousness, to develop Shock Index (SI), Mordified Shock Index (MSI), Age Shock Index (Age SI), Age Mordified Shock Index (Age MSI), and Respiratory Adjusted Shock Index (RASI), as well as other physiological indicators, as tools for assessing, tracking, worsening, and improving the clinical symptoms of COVID-19 patients. For patients with mild to severe illness, and in response to the shortage of manpower during a large influx of emergency patients, this study employs simple and easy-to-use assessment methods, which can be further aided by artificial intelligence technology to facilitate early response and medication.

Study Type

Observational

Enrollment (Estimated)

15000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Taiwan
      • Chiayi City, Taiwan, 60069
        • Recruiting
        • St. Martin De Porres Hospital
      • Tainan, Taiwan, 60069
        • Recruiting
        • St. Martin De Porres Hospital
        • Contact:
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

The COVID-19 patient received treatment at the hospital between May 2022 and March 2027 from emergency room, OPD

Description

Inclusion Criteria:

  • Reviewing the patient's medical history, the primary focus was on hospital records and existing physiological parameters such as blood pressure, heart rate, respiratory rate, and level of consciousness. The patient received treatment at the hospital between May 2022 and March 2027

Exclusion Criteria:

  • Excluding patients with incomplete clinical data or missing information in their medical records.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
COVID-19 patient
The COVID-19 patients were devided into admission ,OPD groups
Other: physiological parameters
systolic blood pressure, diastolic blood pressure , heart rate, respiratory rate , GCS

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Shock index(SI) in the management of COVID -19
Time Frame: 2022 May to 2027 March
SI= heart rate / systolic blood pressre
2022 May to 2027 March
Mordified shock index(MSI) in the management of COVID -19
Time Frame: 2022 May to 2027 March
MSI=heart rate / mean arterial pressure
2022 May to 2027 March
Age shock index(Age SI) in the management of COVID -19
Time Frame: 2022 May to 2027 March
Age shock index =Age x (heart rate / systolic blood pression)
2022 May to 2027 March
Respiratory adjusted shock index (RASI) in the management of COVID-19
Time Frame: 2022 may to 2027 March
Respiratory adjusted shock index =(heart rate/systolic blood pression) x (repiratory rate/10)
2022 may to 2027 March

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

St. Martin De Porress Hospital

Investigators

  • Principal Investigator: Chia-Hsi Chen, Physician, St. Martin De Porress Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

April 1, 2026

Primary Completion (Estimated)

March 11, 2027

Study Completion (Estimated)

March 31, 2027

Study Registration Dates

First Submitted

March 16, 2026

First Submitted That Met QC Criteria

March 25, 2026

First Posted (Actual)

March 31, 2026

Study Record Updates

Last Update Posted (Actual)

March 31, 2026

Last Update Submitted That Met QC Criteria

March 25, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 26B-005 (Other Identifier: St. Martin De Porres Hospital)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Under the privacy of patients the data of medical record can't be shared with others researchers.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on COVID-19 (Coronavirus Disease 2019)

Clinical Trials on physiological parameters

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Korea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe